ADC Therapeutics SA
ADCT3.120USD
-0.160-4.88%
收盘 07/28, 16:00（美东）报价延迟15分钟
309.44M总市值
亏损市盈率 TTM
关于 ADC Therapeutics SA 公司
ADC Therapeutics SA 是一家总部位于瑞士的临床阶段肿瘤药物发现和开发公司。该公司开发抗体药物偶联物 (ADC)，用于治疗实体癌和血液癌。该公司采用针对特定肿瘤抗原的单克隆抗体与一类基于吡咯并苯二氮卓 (PBD) 的弹头结合，以选择性地靶向和杀死癌细胞。该公司有多个基于 PBD 的 ADC 正在进行临床试验，从首次人体试验到关键的 II 期临床试验，以及许多正在开发的临床前 ADC。其主要候选药物是用于治疗淋巴瘤和白血病的 ADCT-301 和用于治疗非霍奇金淋巴瘤和 B 细胞白血病的 ADCT-402。该公司为美国、瑞士和英国的客户提供服务。
公司简介
公司代码ADCT
公司名称ADC Therapeutics SA
上市日期May 15, 2020
成立日期2011
CEOMr. Ameet Mallik
员工数量263
证券类型Ordinary Share
年结日May 15
公司地址Biopole
城市EPALINGES
上市交易所NYSE Consolidated
国家Switzerland
邮编1066
电话41216530200
网址https://adctherapeutics.com/
公司代码ADCT
上市日期May 15, 2020
成立日期2011
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Dr. Tyrell J. Rivers, Ph.D.
Dr. Tyrell J. Rivers, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki
Mr. Mohamed Zaki
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
180.50K
+26.54%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月19日 周四
更新时间: 6月19日 周四
持股股东
股东类型
持股股东
持股股东
占比
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
持股股东
持股股东
占比
Redmile Group, LLC
15.80%
Prosight Capital
9.62%
HPWH TH AG
8.74%
Point72 Asset Management, L.P.
7.90%
OrbiMed Advisors, LLC
6.02%
Other
51.92%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
26.07%
Hedge Fund
18.79%
Corporation
15.04%
Investment Advisor
7.91%
Research Firm
7.20%
Individual Investor
6.59%
Private Equity
6.02%
Bank and Trust
0.83%
Insurance Company
0.02%
Other
11.53%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
208
88.44M
89.17%
-13.33M
2025Q1
217
80.51M
81.56%
-23.93M
2024Q4
219
81.03M
83.80%
-19.29M
2024Q3
223
79.78M
82.57%
-21.86M
2024Q2
215
76.61M
81.35%
-7.96M
2024Q1
177
59.13M
71.30%
-27.56M
2023Q4
169
58.32M
71.49%
-25.86M
2023Q3
180
68.48M
85.02%
-18.63M
2023Q2
182
74.11M
92.00%
-12.88M
2023Q1
185
75.45M
93.66%
-4.11M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Redmile Group, LLC
15.67M
15.8%
--
--
Mar 31, 2025
Prosight Capital
9.54M
9.62%
+28.00K
+0.29%
Mar 31, 2025
HPWH TH AG
8.67M
8.74%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.83M
7.9%
+7.83M
--
Jun 16, 2025
OrbiMed Advisors, LLC
5.97M
6.02%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
4.54%
-88.38K
-1.93%
Mar 31, 2025
Oaktree Capital Management, L.P.
4.02M
4.05%
+4.02M
--
Apr 25, 2024
AstraZeneca (UK) Ltd.
4.01M
4.04%
--
--
Dec 31, 2023
Morgan Stanley & Co. LLC
2.96M
2.98%
-968.19K
-24.66%
Mar 31, 2025
Auven Therapeutics General LP
2.23M
2.25%
-4.10M
-64.75%
Apr 23, 2024
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
iShares Micro-Cap ETF
占比0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
